- Home
- CGC vs FENC Comparison
CGC vs FENC Comparison
Compare CGC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.2M | 366.8M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CGC | FENC |
|---|---|---|
| Price | $0.65 | $10.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | ★ 2.3M | 106.1K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.17 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | $12,759,000.00 | ★ $44,642,000.00 |
| Revenue This Year | $18.83 | $62.55 |
| Revenue Next Year | $7.72 | $42.10 |
| P/E Ratio | ★ N/A | $182.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $5.65 |
| 52 Week High | $2.38 | $13.25 |
Technical Indicators
Market Signals| Indicator | CGC | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 24.25 | 47.19 |
| Support Level | N/A | $9.87 |
| Resistance Level | $1.15 | $10.66 |
| Average True Range (ATR) | 0.04 | 0.53 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 6.62 | 36.23 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.